Juan Camilo Arjona Ferreira
Chief Tech/Sci/R&D Officer at ORGANON & CO.
Net worth: 244 $ as of 2024-03-30
Profile
Juan Camilo Arjona Ferreira is currently the Chief Medical Officer & Head of R&D at Organon & Co. Prior to his current position, he held the role of Chief Medical Officer at Myovant Sciences Ltd.
from 2017 to 2023.
Before that, he served as the Senior Vice President of Clinical Development at Shionogi, Inc. from 2014 to 2017.
From 2002 to 2014, he worked as the Executive Director of Clinical Research at Merck & Co., Inc. Dr. Arjona Ferreira obtained his graduate degree from Universidad del Rosario in 1993.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ORGANON & CO.
0.00% | 2024-03-28 | 13 ( 0.00% ) | 244 $ | 2024-03-30 |
Juan Camilo Arjona Ferreira active positions
Companies | Position | Start |
---|---|---|
ORGANON & CO. | Chief Tech/Sci/R&D Officer | 2023-09-04 |
Former positions of Juan Camilo Arjona Ferreira
Companies | Position | End |
---|---|---|
MYOVANT SCIENCES LTD. | Chief Tech/Sci/R&D Officer | 2023-04-30 |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Chief Tech/Sci/R&D Officer | 2017-06-30 |
MERCK & CO., INC. | Corporate Officer/Principal | 2014-02-28 |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
Training of Juan Camilo Arjona Ferreira
Universidad del Rosario | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
ORGANON & CO. | Health Technology |
Private companies | 3 |
---|---|
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Juan Camilo Arjona Ferreira